| Company Name | Pfizer |
|---|---|
| Protocol Number | A6181222 |
| Title of Study | Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan, A Retrospective NHIA Database Analysis |
| Primary Objective | 1. To identify the incidence and the prevalence of mRCC in the Taiwanese population 2. To describe the prescribing pattern of different TKIin Taiwanese mRCC patients 3. To estimate the overall survival in different TKI users 4. To evaluate the incidence of different TKI -related hypertension |
| Number of Sites | N/A |
| Period of Study | From：2016/08/31 to：2018/12/31 |
| Number of Patients | N/A人 |
| IRB Approval Date | 2016/10/30 |
| Publication Plan / Date | 2019/06/30 |
